NKE vs PFE: Which Is the Better Buy?
Side-by-side comparison of NIKE, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
NIKE, Inc. · Consumer Cyclical
$42.62
+45.5% upside to fair value
Med Conviction
Grade B+
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction
Grade B+
QuantHub Verdict
NKE has more upside to fair value
(+45.5%).
PFE trades at a lower forward P/E
(9.5x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
NKE |
PFE |
| Current Price |
$42.62 |
$26.91 |
| Fair Value Estimate |
$62.00 |
$35.00 |
| Upside to Fair Value |
+45.5%
|
+30.1%
|
| Market Cap |
$63.0B |
$153.0B |
| Forward P/E |
27.9x
|
9.5x
|
| EV / EBITDA |
20.7x
|
13.8x
|
| Price / Sales |
1.4x
|
2.4x
|
| Price / FCF |
19.4x
|
16.8x
|
| Revenue Growth YoY |
-9.8%
|
-1.6%
|
| Gross Margin |
42.7%
|
70.3%
|
| Operating Margin |
8.0%
|
24.7%
|
| Return on Equity |
24.4%
|
9.0%
|
| Dividend Yield |
3.8% |
6.4% |
| FCF Yield |
5.2%
|
5.9%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Nike is the world's largest athletic footwear and apparel company with $46.3B in FY2025 revenue, operating across 190+ countries with the Nike, Jordan, and Converse brands. The stock trades near its 9-year low at $42.62 after an 11% single-day crash following a Q3 FY2026 earnings report that showed 35% net income decline and weak Q4 guidance calling for a further 2-4% revenue decline. FY2025 reve…
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
| Metric |
NKE |
PFE |
| Zone Low |
$44.00 |
$25.00 |
| Zone High |
$50.00 |
$29.00 |
| In Buy Zone? |
Yes
|
Yes
|